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Despite the high degree of sequence homology between adeno-associated virus (AAV) serotype 1 and 6
capsids (99.2%), these viruses have different liver transduction profiles when tested as vectors. Examination of
the six amino acid residues that differ between AAV1 and AAV6 revealed that a lysine-to-glutamate change
(K531E) suppresses the heparin binding ability of AAV6. In addition, the same mutation in AAV6 reduces
transgene expression to levels similar to those achieved with AAV1 in HepG2 cells in vitro and in mouse liver
following portal vein administration. In corollary, the converse E531K mutation in AAV1 imparts heparin
binding ability and increases transduction efficiency. Extraction of vector genomes from liver tissue suggests
that the lysine 531 residue assists in preferential transduction of parenchymal cells by AAV6 vectors in
comparison with AAV1. Lysine 531 is unique to AAV6 among other known AAV serotypes and is located in a
basic cluster near the spikes that surround the icosahedral threefold axes of the AAV capsid. Similar to studies
with autonomous parvoviruses, this study describes the first example of single amino acid changes that can
explain differential phenotypes such as viral titer, receptor binding, and tissue tropism exhibited by closely
related AAV serotypes. In particular, a single lysine residue appears to provide the critical minimum charged
surface required for interacting with heparin through electrostatic interaction and simultaneously plays an
unrelated yet critical role in the liver tropism of AAV6 vectors.
The diverse tissue tropisms exhibited by different serotypes
of adeno-associated virus (AAV) vectors have enabled their
widespread application in therapeutic gene transfer in vitro
and in vivo (for reviews, see references 1 and 24). Such pref-
erential transduction of select tissue types by AAV serotypes
can possibly be explained, at least in part, by initial cell surface
binding of the viral capsid to complex cell surface glycosami-
noglycans (2). For example, AAV serotype 2 has been shown
to utilize heparan sulfate as a primary receptor for cell attach-
ment (18). Intriguingly, the ability of AAV2 to transduce dif-
ferent types of myofibers, such as slow and fast twitch muscle,
has been shown to correlate with the expression of heparan
sulfate (14). Similarly, the tropism of AAV serotype 5 for
airway epithelial cells appears to correlate with its ability to
utilize sialic acid for cell surface binding (22).
Despite the high degree of sequence homology between
AAV1 and AAV6 capsids (99.2%), the two serotypes display
several unique characteristics. For example, previous studies
have shown that AAV6 vectors display increased liver trans-
duction compared to AAV1 (3). Another distinguishing fea-
ture of AAV1 and AAV6 vectors is the ability of the latter
serotype to bind heparin with moderate affinity (4). However,
the AAV6 capsid does not possess R585 and R588 residues
involved in heparin binding by AAV2 (8, 12). These observa-
tions suggest that the molecular determinants of heparin bind-
ing and possibly liver tropism might lie within the six amino
acid residues that differ between AAV6 and AAV1.
To identify a critical residue(s) involved in the aforemen-
tioned features unique to AAV6, we generated a series of
AAV1 and AAV6 mutants by site-directed mutagenesis
(QuikChange; Stratagene) on plasmids pXR1 (15) and pXR6
(a kind gift from Joseph Rabinowitz at Thomas Jefferson Uni-
versity). Positions of the six amino acids (five located in the
VP3 subunit and one in VP1) that were swapped between
AAV1 and AAV6 capsids, genome titers of AAV1/AAV6 mu-
tant vectors packaging the firefly luciferase transgene cassette
determined as described previously (19) (Table 1), and their
respective heparin binding profiles (Fig. 1a and b) are shown.
Of the six amino acids studied, swapping amino acids at posi-
tion 129, 584, or 598 between AAV6 and AAV1 independently
and reproducibly affected viral genome titers (Table 1). The
increase in titer from AAV1 recombinants 129, 584, and 598
was of keen interest, since these vector yields exceeded those
of both parent serotypes and suggested that further improve-
ments in other serotype-specific titers may also be improved by
single amino acid changes (Table 1). Similar outcomes have
been observed in mutants isolated from combinatorial libraries
of AAV capsids generated by a method analogous to DNA
shuffling, an approach independent of rational design (11). The
increased titers in the case of the aforementioned AAV1 mu-
tants can possibly be explained by improved folding/stability of
capsid protein subunits and/or packaging efficiency (9, 23).
With respect to loss or gain of affinity to heparin, our mutant
collection further helped identify a single amino acid change
responsible for such binding activity. Binding of parental
AAV1, AAV2, AAV6, and AAV1/AAV6 mutants packaging a
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firefly luciferase transgene to heparin-conjugated agarose type
I (H-6508; Sigma) was analyzed by loading affinity columns
(Bio-Rad microspin column) with 5  1010 particles of each
viral stock in 500 l Ringer’s saline solution (RSS) followed by
the sequential collection of fractions from flowthrough, wash
with RSS, and elution with RSS containing 800 mM NaCl. The
number of mutant or parental AAV particles present in each
fraction was determined by dot blot hybridization.
As shown in Fig. 1a, the heparin column elution profile of
the AAV6-K531E mutant is identical to that of AAV1, sug-
gesting an attenuation of heparin binding ability. The remain-
ing five amino acid changes, however, fail to alter the ability of
AAV6 to bind heparin. These results are further corroborated
in Fig. 1b, where the reciprocal change in AAV1-E531K im-
parts heparin-binding characteristics onto the AAV1 capsid,
similar to wild-type AAV2 and AAV6. Swapping other amino
acid residues from AAV6 onto AAV1 does not impart heparin
binding. Further, as shown in Fig. 1c, the elution profile of
AAV capsids from heparin agarose columns at different salt
concentrations suggests that AAV6 and AAV1-E531K bind
FIG. 1. (a) Heparin binding profile of AAV6 mutants. (b) Heparin binding profile of AAV1 mutants. (c) Elution profiles of AAV2, AAV6, and
AAV1-E531K at different salt concentrations. Mutants at the 531 position are shown in boldface letters. (d) Heparin binding profile of AAV8 and
AAV8-E533K. L, load; FT, flowthrough; W, wash; E, eluate.
TABLE 1. Virus titers for mutants based on AAV1 and AAV6
Virus Titer (v.g./ml)a






AAV1-N642H ....................................................................6.02E  1011






AAV6-H642N ....................................................................4.44E  1011
a v.g., virus genome.
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heparin with slightly lower affinity (200 to 300 mM) compared
to AAV2 (300 to 400 mM). Taken together, these data suggest
that lysine 531 is the core residue at a low-affinity heparin
binding site on the AAV6 capsid. The K531 residue is unique
to AAV6 among currently known serotypes, which contain a
conserved glutamate or aspartate residue at the corresponding
531 position (13, 16). Identical alteration in serotype 8 also
conferred heparin binding (Fig. 1d), supporting the impor-
tance of the K531 position in the type 6 VP3 capsid subunit.
The ability to alter type 8 capsid heparin binding activity sug-
gests that the heparin binding phenotype conferred by this
single amino acid change is not restricted to closely related
AAV1 and AAV6 serotypes.
The potential contribution of lysine 531 to surface properties
of the AAV6 capsid (and of E531 to that of AAV1) was
analyzed by generating three-dimensional models of the sur-
face charge distribution on the VP3 subunit (Fig. 2) of either
serotype utilizing Swiss Model (17) with available coordinates
of AAV2 (20) (Protein Databank accession no. 1LP3) supplied
as a template (13). As shown in Fig. 2, insets a, b, and c, we
have compared the capsid surface disposition of equivalent
residues to those previously mapped for AAV2 heparin bind-
ing as well as neighboring basic residues located on icosahedral
threefold symmetry-related VP3 subunits. The key positive
residues and the 531 residue are proximal to the spikes that
surround this symmetry axis. When the capsid is viewed per-
pendicular to the threefold axis, the side chain for K531 is
surface exposed and forms a continuation for the basic patch
between K533 and R488 as well as K528 and R567 at the base
of each threefold spike of the AAV6 capsid surface model
(Fig. 2, inset b, continuous blue patch, boxed with a dotted
yellow line). Such presentation of a continuous cationic patch
is reminiscent of that seen in the AAV2 crystal structure in this
capsid region, comprised of basic residues R487, R527, R566,
R585, and R588 (Fig. 2, inset a, continuous blue patch, boxed
with a dotted yellow line), even though it contains E530 at the
position equivalent to K531 in AAV6. In contrast, the nega-
tively charged E531 in AAV1 forms a discontinuous positively
charged surface (Fig. 2, inset c, broken blue patch, boxed with
a dotted yellow line) which is incapable of heparin binding.
Thus, a minimum continuous positive surface appears to be
necessary for the electrostatic interaction of the AAV capsid
with heparin rather than the exact disposition of the residues.
We next investigated whether lysine 531, which appears to
be a critical distinguishing feature between AAV6 and AAV1,
might possibly explain the enhanced transduction potential of
FIG. 2. Three-dimensional surface maps and charge distribution of a trimer of VP3 subunits viewed perpendicular to the icosahedral threefold
symmetry axis for the AAV2 crystal structure as well as AAV6 and AAV1 models. All basic residues (lys, arg, his) are shown in blue, and the acidic
residues (glu, asp) are shown in red. The insets (zoomed in) below represent magnification of black boxed regions showing (a) the position of E530
residue at the AAV2 threefold axis with heparin binding residues R585 and R588 forming a continuous basic blue patch (boxed inside a yellow
dotted line); (b) the position of the K531 residue at the AAV6 threefold connecting residues R487, K528, K533, and K567 to form a continuous
basic blue patch similar to AAV2 (boxed inside a yellow dotted line), albeit proximal to the threefold spikes; and (c) position of the E531 residue
at the AAV1 threefold axis forming a discontinuous basic patch (boxed inside a yellow dotted line). Models were generated as described in the
text, and images were rendered using Pymol.
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AAV6 compared to AAV1 in hepatocytes in vitro and in vivo.
The human coagulation factor IX (hFIX) expression cassette
driven by a liver-specific transthyretin promoter was packaged
into AAV1, AAV1-E531K, AAV6, and AAV6-K531E capsids
to generate self-complementary AAV vectors. In addition,
conventional AAV vectors packaging the firefly luciferase
transgene were also generated, and vector genome titers were
determined by dot blot hybridization. As shown in Fig. 3a, the
luciferase transgene expression level achieved using AAV6
vectors is nearly 1 log unit higher than that obtained with
AAV1 vectors in HepG2 cells in vitro. The K531E mutation in
AAV6 reduces the luciferase expression level to that of AAV1,
while the converse E531K change in AAV1 appears to sub-
stantially enhance the transduction efficiency of AAV1 in vitro.
For assessment of in vivo transduction, vectors packaging
the hFIX expression cassette were infused into the portal vein
of 6-week-old male C57BL/6 mice (Jackson Laboratories, Bar
Harbor, ME) at a dose of 5  1010 particles per mouse. Blood
was collected at 1 week and 6 weeks postinfusion, and hFIX
levels in plasma were determined by hFIX enzyme-linked im-
munosorbent assay (21). As shown in Fig. 3b, serum hFIX
levels at 1 and 6 weeks following administration of AAV6
vectors is approximately an order of magnitude higher than
those achieved with AAV1 vectors. In the case of AAV6-
K531E vectors, hFIX expression is reduced to levels obtained
with AAV1, identical to in vitro results and suggesting that
K531 is critical for enhanced liver transduction by AAV6.
These results are supported further by the increased hFIX
levels obtained with AAV1-E531K vectors, albeit at lower lev-
els than those achieved with AAV6. The aforementioned ob-
servation can possibly be attributed to the potential role(s)
played by the remaining five residues that differ between
AAV1 and AAV6 in facilitating favorable interactions between
the AAV6 capsid and liver tissue. It is also noteworthy to
mention that preincubation of AAV6 vectors with heparin
does not block AAV6 transduction in HepG2 cells in vitro
(data not shown). These results suggest that the heparin bind-
ing ability and liver tropism of AAV6 might constitute two
unrelated phenotypic characteristics caused by the same lysine
531 residue.
To further characterize AAV capsid interactions with hepa-
tocytes, mouse liver parenchymal (PC) and nonparenchymal
cells (NPC) were isolated at 6 weeks postadministration of
different vectors using the method described by Kawakami et
al. (7), with some modifications. Briefly, mice were sacrificed,
and their livers were perfused with phosphate-buffered saline
(PBS) containing 0.05% (wt/vol) collagenase for about 20 min.
Following excision of the liver, cells were dispersed by gentle
stirring in ice-cold PBS, filtered through cotton mesh sieves,
and centrifuged for 1 min at 50  g to separate liver PC and
NPC in the pellet and supernatant, respectively. This process
was repeated several times with the PC pellet and NPC super-
natant fractions to remove contaminating cell types. Total
DNA from PC and NPC was extracted using the DNeasy kit
(QIAGEN). Dot blot DNA hybridization was performed using
a radiolabeled hFIX cDNA-derived probe. As shown in Fig.
3c, the amounts of accumulated DNA in PC from different
vectors correlate well with their hFIX expressions. Significantly
larger amounts of vector DNA from AAV6 were detected in
PC compared to those of AAV1. The K-to-E change in the
AAV6 capsids reduced the amount of vector DNA in PC to a
level similar to that of AAV1, while the converse E-to-K
change in AAV1 capsids markedly increased the amount of
vector DNA accumulated in PC. These data suggest that, in
addition to heparin binding, the lysine 531 residue plays a key
role in uptake of AAV6 in PC.
In summary, of the six amino acids that differ between AAV
types 1 and 6, residues at positions 129, 584, and 598 appear
critical in determining viral genome titer. In addition, we have
identified a single amino acid (K531) that is essential for con-
ferring the heparin binding characteristics of AAV6. Introduc-
tion of an E531K change in AAV1 imparts a heparin binding
ability similar to that of AAV6. These observations suggest
that a minimum basic footprint is required to facilitate heparin
binding through electrostatic interactions. Introduction of
K531 in AAV type 8 capsid resulted in recombinant vector
particles with heparin binding activity similar to that of AAV6
(Fig. 1d). These data not only speak to the importance of the
K531 position but also illustrate the ability of a single amino
acid change to confer a serotype-specific trait in another dis-
tantly related serotype. We also found that lysine 531 is im-
portant for higher transduction of hepatocytes by AAV6 than
by AAV1. Although competitive inhibition study with heparin
FIG. 3. (a) Luciferase transgene expression levels achieved using
AAV1 and AAV6 compared with mutants AAV1-E531K and AAV6-
K531E in HepG2 cells (n  3). (b) Serum hFIX levels at 1 week and
6 weeks following portal vein infusion of wild-type and mutant AAV1
and AAV6 self-complementary (sc) vectors (5  1010/mouse) packag-
ing the hFIX transgene driven by the transthyretin promoter (n  4).
(c) Vector genome levels in parenchymal (PC) and nonparenchymal
cells (NPC) at 6 weeks following portal vein infusion of wild-type and
mutant AAV1 and AAV6 vectors. Total DNA from PC and NPC
isolated from collagenase-treated mouse livers was extracted using the
DNeasy kit (QIAGEN). RLU, relative light units.
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suggests that heparan sulfate is not a receptor for AAV6 in the
cell types tested in this study, it is likely that the lysine 531
residue might mediate uptake through an unknown alternative
mechanism(s). Nevertheless, the results described herein al-
low, for the first time, a partial mechanistic interpretation of
the molecular determinants of liver tropism in AAV6 vectors
in comparison with AAV1.
It should be noted that similar studies with autonomous
parvoviruses suggest that the molecular determinants control-
ling host range and tropism in autonomous parvoviruses can
often be narrowed down to a few critical amino acid residues
in the capsid. For example, the feline panleukopenia virus
(FPV) and its host range variant, canine parvovirus (CPV), can
both bind the feline transferrin receptor, while only CPV binds
to the canine transferrin receptor (cTfR). Introducing two
CPV-specific changes into FPV allowed FPV to bind the ca-
nine transferrin receptor-infected canine cells, although nei-
ther change alone altered such phenotypes (5). More recently,
studies with the minute virus of mice suggested that single
amino acid changes at the sialic acid binding pocket of the
capsid can modulate tropism and determine virulence (10). In
the case of AAV, only two types of glycosaminoglycan-based
primary receptors, heparan sulfate and sialic acid, have been
identified thus far. While AAV2 binds heparan sulfate, AAV4
and AAV5 as well as AAV1 and AAV6 have been shown to
exploit sialic acid residues with different linkage specificities
for cellular entry (6, 22, 25). We anticipate that further studies
mapping the potential role of single amino acid changes in
closely related AAV serotypes and variants, as described above
for AAV1 and AAV6, are likely to shed light on molecular
determinants of capsid-receptor interactions, tissue tropism,
immune profile, and other aspects of the AAV life cycle in
general. Such structure-function studies will lay the foundation
for rational engineering of cell type-specific AAV vectors in
targeted gene delivery applications.
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